{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:17:48Z","timestamp":1790842668386,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.beha.2020.101171","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T20:58:32Z","timestamp":1588107512000},"page":"101171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Juvenile myelomonocytic leukemia \u2013 A bona fide RASopathy syndrome"],"prefix":"10.1016","volume":"33","author":[{"given":"Terra","family":"Lasho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.beha.2020.101171_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6465","key":"10.1016\/j.beha.2020.101171_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.beha.2020.101171_bib3","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet"},{"issue":"16","key":"10.1016\/j.beha.2020.101171_bib4","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1182\/blood-2014-03-300319","article-title":"Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia","volume":"124","author":"Chang","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2020.101171_bib5","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25104","article-title":"Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management","volume":"93","author":"Patnaik","year":"2018","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.beha.2020.101171_bib6","first-page":"3534","article-title":"Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)","volume":"89","author":"Niemeyer","year":"1997","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2020.101171_bib7","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.4161\/cc.5.15.3128","article-title":"Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders","volume":"5","author":"Kratz","year":"2006","journal-title":"Cell Cycle"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101171_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/10245330512331390078","article-title":"Juvenile myelomonocytic leukemia","volume":"10","author":"Kratz","year":"2005","journal-title":"Hematology"},{"issue":"6","key":"10.1016\/j.beha.2020.101171_bib9","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/blood-2005-02-0531","article-title":"The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome\/myeloproliferative disease","volume":"106","author":"Kratz","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2020.101171_bib10","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3324\/haematol.2014.114595","article-title":"RAS diseases in children","volume":"99","author":"Niemeyer","year":"2014","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.beha.2020.101171_bib11","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2018-11-844688","article-title":"Juvenile myelomonocytic leukemia: who's the driver at the wheel?","volume":"133","author":"Niemeyer","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2020.101171_bib12","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/sj.leu.2404303","article-title":"A novel somatic K-Ras mutation in juvenile myelomonocytic leukemia","volume":"20","author":"Reimann","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2020.101171_bib13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ng1748","article-title":"Germline KRAS mutations cause Noonan syndrome","volume":"38","author":"Schubbert","year":"2006","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.beha.2020.101171_bib14","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ajhg.2010.06.015","article-title":"Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype","volume":"87","author":"Martinelli","year":"2010","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.beha.2020.101171_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.beha.2020.101171_bib16","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-017-02177-w","article-title":"RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia","volume":"8","author":"Lipka","year":"2017","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.beha.2020.101171_bib17","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood-2014-08-550483","article-title":"How I treat juvenile myelomonocytic leukemia","volume":"125","author":"Locatelli","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2020.101171_bib18","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/leu.2013.82","article-title":"Autoimmunity and persistent RAS-mutated clones long after the spontaneous regression of JMML","volume":"27","author":"Takagi","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2020.101171_bib19","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41375-018-0343-2","article-title":"Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia","volume":"33","author":"Krombholz","year":"2019","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.beha.2020.101171_bib20","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1093\/hmg\/ddu148","article-title":"Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis","volume":"23","author":"Flex","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"12","key":"10.1016\/j.beha.2020.101171_bib21","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1038\/sj.onc.1202517","article-title":"TC21 and Ras share indistinguishable transforming and differentiating activities","volume":"18","author":"Graham","year":"1999","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.beha.2020.101171_bib22","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/leu.2008.162","article-title":"Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia","volume":"22","author":"Emanuel","year":"2008","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2020.101171_bib23","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"Ricci","year":"2010","journal-title":"Clin Canc Res"},{"issue":"6","key":"10.1016\/j.beha.2020.101171_bib24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.23702","article-title":"Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia","volume":"89","author":"Cervera","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.beha.2020.101171_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.25684","article-title":"Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management","volume":"95","author":"Patnaik","year":"2020","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.beha.2020.101171_bib26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000227023","article-title":"Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia","volume":"49","author":"Nakagawa","year":"1992","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.beha.2020.101171_bib27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ajh.23410","article-title":"Prognostic impact of RAS mutations in patients with myelodysplastic syndrome","volume":"88","author":"Al-Kali","year":"2013","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.beha.2020.101171_bib28","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2020.101171_bib29","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2015.337","article-title":"Age-related mutations and chronic myelomonocytic leukemia","volume":"30","author":"Mason","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.beha.2020.101171_bib30","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/ng.3420","article-title":"Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network","volume":"47","author":"Caye","year":"2015","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.beha.2020.101171_bib31","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng.2698","article-title":"Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia","volume":"45","author":"Sakaguchi","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.beha.2020.101171_bib32","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1203\/PDR.0b013e3181961d2a","article-title":"Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia","volume":"65","author":"Yoshida","year":"2009","journal-title":"Pediatr Res"},{"issue":"3","key":"10.1016\/j.beha.2020.101171_bib33","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2014-09-601690","article-title":"Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia","volume":"125","author":"Stieglitz","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2020.101171_bib34","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2141.2010.08393.x","article-title":"Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia","volume":"151","author":"Perez","year":"2010","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2020.101171_bib35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2141.2010.08196.x","article-title":"Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations","volume":"150","author":"Sugimoto","year":"2010","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.beha.2020.101171_bib36","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2006-09-046649","article-title":"Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations","volume":"109","author":"Matsuda","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2020.101171_bib37","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2141.2010.08525.x","article-title":"Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia","volume":"152","author":"Loh","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2020.101171_bib38","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2004-05-1944","article-title":"Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS\/EBMT trial","volume":"105","author":"Locatelli","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101171_bib39","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1200\/JCO.1997.15.2.566","article-title":"Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood","volume":"15","author":"Locatelli","year":"1997","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.beha.2020.101171_bib40","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood-2015-01-619734","article-title":"Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group","volume":"125","author":"Cseh","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2020.101171_bib41","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/15592294.2017.1356959","article-title":"Epigenetic dysregulation of the erythropoietic transcription factor KLF1 and the beta-like globin locus in juvenile myelomonocytic leukemia","volume":"12","author":"Fluhr","year":"2017","journal-title":"Epigenetics"},{"issue":"18","key":"10.1016\/j.beha.2020.101171_bib42","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1182\/blood-2010-08-298968","article-title":"Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome","volume":"117","author":"Olk-Batz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101171_bib43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13148-016-0216-3","article-title":"CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia","volume":"8","author":"Fluhr","year":"2016","journal-title":"Clin Epigenet"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:06:19Z","timestamp":1761498379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692620300323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1521692620300323"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2020.101171","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Juvenile myelomonocytic leukemia \u2013 A bona fide RASopathy syndrome","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2020.101171","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101171"}}